Proceedings of the National Academy of Sciences · 1994 · 415 citations · 30 references
Life SciencesBiochemistryNeurologyDementiaMolecular NeuroscienceNeurodegenerationAlzheimer DiseaseAmyloid FormationNeurodegenerative DiseasesNeurodegenerative DisordersProtein AggregationProtein Aggregation DisordersAlzheimer Disease ProgressionAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid ClearanceAmyloid InhibitionAmyloid SuppressionAmyloidogenic ProteinsInhibition Of Amyloid Formation
The cardinal pathological features of Alzheimer disease are depositions of aggregated amyloid beta protein (A beta) in the brain and cerebrovasculature. However, the A beta is found in a soluble form in cerebrospinal fluid in healthy individuals and patients with Alzheimer disease. We postulate that sequestration of A beta precludes amyloid formation. Failure to sequester A beta in Alzheimer disease may result in amyloidosis. When we added A beta to cerebrospinal fluid of patients and controls it was rapidly sequestered into stable complexes with transthyretin. Complexes with apolipoprotein E, which has been shown to bind A beta in vitro, were not observed in cerebrospinal fluid. Additional in vitro studies showed that both purified transthyretin and apolipoprotein E prevent amyloid formation.
30
The Metabolic Basis of Inherited Disease
Annals of Internal Medicine · 1990 · 4K citations
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Peter Seubert, Carmen Vigo‐Pelfrey, Fred Esch et al. · Nature · 1992 · 1.7K citations